Researchers link drop in breast cancer cases to decline in HRT use

Share this article:
US breast cancer rates saw a dramatic decline in 2003, just one year after millions of women stopped using hormone replacement therapy (HRT), a new study found. The new analysis released yesterday shows the number of overall US breast cancer cases dropped 7% from 2002 to 2003, a year after an American Cancer Society study found links between the use of HRT and the disease. The decline in breast cancer cases in older women sensitive to the hormone estrogen was even greater, at 12%, the researchers said. “Something went right in 2003 and it seems that it was the decrease in the use of hormone therapy,” said Peter Radvin, a professor at M.D. Anderson and co-author of the study, in a statement. A study published in September linked the drop in breast cancer rates in 2003 to a reduction in the use of Wyeth’s Premarin, an estrogen replacement product, which was once the top prescribed US pharmaceutical. Wyeth spokeswoman Candace Steele told Bloomberg.com in an e-mailed statement that “It is simply inappropriate to make any speculative statements based on the M.D. Anderson Cancer Center analysis. Even the researchers state they cannot give the definitive cause. Clearly more studies are warranted.”
Share this article:
close

Next Article in News

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.